FLUDARABINE AND TREOSULFAN CONDITIONING FOR ALLOGENEIC STEM-CELL TRANSPLANTATION IN PATIENTS WITH AML AND MDS NOT ELIGIBLE FOR STANDARD MYELOABLATIVE CONDITIONING

被引：0
|
作者：
Shimoni, A. [1 ]
Crotta, A. [2 ]
Shem-Tov, N. [1 ]
Peccatori, J. [2 ]
Yerushalmi, R. [1 ]
Bernardi, M. [2 ]
Nagler, A. [1 ]
Ciceri, F. [2 ]
机构：
[1] Chaim Sheba Med Ctr, Tel Hashomer, Israel
[2] Ist Sci San Raffaele, Milan, Italy
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0440
引用
收藏
页码：177 / 177
页数：1
相关论文
共 50 条
  • [1] Fludarabine and treosulfan conditioning for allogeneic stem cell transplantation (SCT) in patients with AML and MDS not eligible for standard myeloablative conditioning: the role of treosulfan dose
    Shimoni, A.
    Peccatori, J.
    Shem-Tov, N.
    Lo Russo, A.
    Yerushalmi, R.
    Bernardi, M.
    Nagler, A.
    Ciceri, F.
    [J]. BONE MARROW TRANSPLANTATION, 2013, 48 : S220 - S220
  • [2] Treosulfan/fludarabine - a low toxicity but myeloablative conditioning for allogeneic hematopoietic stem cell transplantation
    Holowiecki, J
    Giebel, S
    Wojnar, J
    Krawczyk-Kulis, M
    Wylezol, I
    Kruzel, T
    Markiewicz, M
    [J]. BLOOD, 2004, 104 (11) : 292A - 292A
  • [3] Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation
    Remberger, Mats
    Torlen, Johan
    El Serafi, Ibrahim
    Garming-Legert, Karin
    Bjorklund, Andreas
    Ljungman, Per
    Sundin, Mikael
    Hassan, Moustapha
    Mattsson, Jonas
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 106 (04) : 471 - 475
  • [4] Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation
    Mats Remberger
    Johan Törlen
    Ibrahim El Serafi
    Karin Garming-Legert
    Andreas Björklund
    Per Ljungman
    Mikael Sundin
    Moustapha Hassan
    Jonas Mattsson
    [J]. International Journal of Hematology, 2017, 106 : 471 - 475
  • [5] Comparable Survival for Fludarabine and Treosulfan Vs. Fludarabine and TBI As Conditioning Regimens in Patients with AML and MDS Undergoing Allogeneic Stem Cell Transplantation
    Kolloch, Lina
    Berning, Philipp
    Reicherts, Christian
    Call, Simon
    Marx, Julia
    Floeth, Matthias
    Esseling, Eva
    Ronnacker, Julian
    Mikesch, Jan-Henrik
    Schliemann, Christoph
    Lenz, Georg
    Stelljes, Matthias
    [J]. BLOOD, 2023, 142
  • [6] Conditioning with treosulfan and fludarabine for allogeneic blood stem cell transplantation
    Casper, J
    Steiner, B
    Wolff, D
    Kleine, HD
    Wilhelm, S
    Hammer, U
    von Wurmb, N
    Roeber, S
    Wegener, R
    Freund, M
    [J]. BONE MARROW TRANSPLANTATION, 2001, 27 : S285 - S286
  • [7] Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine/Treosulfan Conditioning Regimen Compared with Busulfan-Based Myeloablative and Reduced-Intensity Conditioning in Patients with AML and Mds; Relative Outcomes Depend On Disease Status at Transplantation
    Shimoni, Avichai
    Rand, Avital
    Shem-Tov, Noga
    Hardan, Izhar
    Volchek, Yulia
    Maayaan, Hannah
    Yerushalmi, Ronit
    Nagler, Arnon
    [J]. BLOOD, 2009, 114 (22) : 1303 - 1304
  • [8] Fludarabine/melphalan conditioning for allogeneic stem cell transplantation (SCT) in elderly patients with AML/MDS
    Kennedy, GA
    Butler, J
    Durrant, S
    Hill, GR
    Western, R
    Morton, J
    [J]. BLOOD, 2005, 106 (11) : 438B - 439B
  • [9] Comparable outcomes for Fludarabine/TBI versus Fludarabine/Treosulfan conditioning prior to allogeneic stem cell transplantation (Allo-SCT) in AML and MDS patients
    Berning, P.
    Kolloch, L.
    Reicherts, C.
    Call, S.
    Marx, J.
    Floeth, M. P.
    Esseling, E.
    Schliemann, C.
    Lenz, G.
    Stelljes, M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 140 - 140
  • [10] Treosulfan in combination with fludarabine as conditioning for allogeneic stem cell transplantation in myelofibrosis
    Kragl, B.
    Heinz, F.
    Grosse-Thie, C.
    Henze, L.
    Lakner, J.
    Freitag, S.
    Wittke, C.
    Brueckner, F.
    Junghanss, C.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 151 - 152
12345